CORT - Corcept Therapeutics Incorporated
| Previous Close | 11.80 |
| Open | 11.71 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 800 |
| Day's Range | 11.11 - 11.87 |
| 52 Week Range | 9.14 - 20.00 |
| Volume | 1,217,026 |
| Avg. Volume | 1,896,660 |
| Market Cap | 1.324B |
| Beta (3Y Monthly) | 1.46 |
| PE Ratio (TTM) | 9.61 |
| EPS (TTM) | 1.19 |
| Earnings Date | Feb 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.80 |
- GlobeNewswire•10 hours ago
Corcept Therapeutics To Announce Audited Financial Results, Provide Corporate Update And Host Conference Call
MENLO PARK, Calif., Feb. 19, 2019 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its audited 2018 fourth quarter and full-year financial.
- Business Wire•8 days ago
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Corcept Therapeutics Incorporated Investors
Glancy Prongay & Murray LLP announces an investigation on behalf of Corcept Therapeutics Incorporated investors concerning the Company and its officers’ possible violations of federal securities laws.
- GlobeNewswire•9 days ago
Recent Analysis Shows Corcept Therapeutics, CDK Global, Dynavax Technologies, ICU Medical, American Vanguard, and Cabot Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•12 days ago
Options Traders Expect Huge Moves in Corcept (CORT) Stock
Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.
- Business Wire•12 days ago
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Corcept Therapeutics Incorporated Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Corcept Therapeutics Incorporated investors concerning the Company and its officers’ possible violations of federal securities laws.
- Simply Wall St.•14 days ago
Investors Are Undervaluing Corcept Therapeutics Incorporated (NASDAQ:CORT) By 49.63%
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! How far off is Corcept Therapeutics Incorporated Read More...
- PR Newswire•14 days ago
Investor Alert: Kaplan Fox Investigates Corcept Therapeutics Incorporated
NEW YORK , Feb. 5, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP ( www.kaplanfox.com ) has been investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" ...
- Schaeffer's Investment Research•14 days ago
Puts Pop Amid Drug Stock's Roller-Coaster Session
Corcept Therapeutics issued a white paper to refute "offensive nonsense" from shorts
- Motley Fool•19 days ago
Here's Why Corcept Therapeutics Fell as Much as 13.7% Today
The company announced preliminary full-year 2018 results that fell below Wall Street's expectations.
- GlobeNewswire•19 days ago
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2018 Preliminary Selected Financial Results; Provides 2019 Revenue Guidance
Corcept Therapeutics Incorporated (CORT), a company engaged in the discovery, development and commercialization of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported preliminary fourth quarter revenue of $66.8 million, compared to $53.3 million in the fourth quarter of 2017. Preliminary 2018 revenue was $251.2 million, an increase of 58 percent from 2017. Corcept projects 2019 revenue of $285 - $315 million.
- GlobeNewswire•25 days ago
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Corcept Therapeutics Incorporated
NEW YORK, Jan. 25, 2019 -- Levi & Korsinsky announces it has commenced an investigation of Corcept Therapeutics Incorporated (“Corcept” or “the Company”) (NASDAQCM: CORT).
- Motley Fool•25 days ago
Here's Why Corcept Therapeutics Stock Fell as Much as 18.5% Today
An investigative report is shining light on some very serious questions about the company. Shareholders absolutely must read it.
- Schaeffer's Investment Research•25 days ago
Corcept Puts Active After Negative Report
SIRF suggests the drug maker is "exploiting gaps" in the U.S. healthcare system
- Simply Wall St.•last month
Can Corcept Therapeutics Incorporated (NASDAQ:CORT) Maintain Its Strong Returns?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...
- Benzinga•2 months ago
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
After extended weakness, biotech stocks turned a corner along with the broader markets to close out the week. With just a session left, it looks less likely the sector ends in the black for the year. The ...
- Insider Monkey•2 months ago
Is Corcept Therapeutics Incorporated (CORT) A Good Stock To Buy?
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients’ money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth depends on it. Regardless of the various methods used by elite investors like David Tepper and Dan Loeb, […]
Investor's Business Daily•2 months agoIBD 50 Stocks To Watch: Corcept Expected To Pick Up Growth In 2019
Biotech Corcept develops drugs to treat cortisol activity, such as Cushing's disease. The chief drug is Korlym, also known as mifepristone.
- ACCESSWIRE•2 months ago
Biotech Companies in the News
HENDERSON, NV / ACCESSWIRE / December 13, 2018 / Here is a list of several Biotech companies in the news that could make investors profits heading into the holiday season. We are highlighting: Endonovo ...
- GlobeNewswire•2 months ago
Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing’s Syndrome
Corcept Therapeutics Incorporated (CORT) announced today that the United States Patent and Trademark Office has given notice that it will allow a patent covering the concomitant use of Korlym® and drugs from the class of medications known as strong CYP3A inhibitors to treat patients with hypercortisolism (Cushing’s syndrome). The patent will expire in 2037. “This patent covers an important finding of our research – that with proper dose modulation, Korlym can safely be administered in combination with medications that are strong CYP3A inhibitors,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer.
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: MYOS RENS Technology and Corcept Therapeutics
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / Shares of MYOS RENS and Corcept Therapeutics were two biotech stocks seeing huge gains in Tuesday’s trading session. MYOS RENS shares soared after news of its product being launched with The Vitamin Shoppe. The fact that a generic version of Corcept Therapeutics’ Korlym drug may not happen for a while had traders cheering and sending the stock higher.
- Motley Fool•2 months ago
Here's Why Corcept Therapeutics Surged Today
It looks like generic versions of the company's Cushing syndrome treatment will hit a roadblock.
- Motley Fool•2 months ago
Here's Why Corcept Therapeutics Rose 18.6% in November
Solid revenue growth and pipeline progress from the biotech fueled the rise.
- GlobeNewswire•3 months ago
Report: Exploring Fundamental Drivers Behind Tesla, Nordson, Paycom Software, PDL BioPharma, Corcept Therapeutics, and Willis Towers Watson Public — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
